Research ExplorerPublicationsBortezomib in combination with intermediate-dose dexamethaso...

Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.

Standard

Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. / Kropff, Martin; Bisping, Guido; Schuck, Elke; Liebisch, Peter; Lang, Nicola; Hentrich, Markus; Dechow, Tobias; Kröger, Nicolaus; Salwender, Hans; Metzner, Bernd; Sezer, Orhan; Engelhardt, Monika; Wolf, Hans-Heinrich; Einsele, Hermann; Volpert, Sarah; Heinecke, Achim; Berdel, Wolfgang E; Kienast, Joachim.

In: BRIT J HAEMATOL, Vol. 138, No. 3, 3, 2007, p. 330-337.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Kropff, M, Bisping, G, Schuck, E, Liebisch, P, Lang, N, Hentrich, M, Dechow, T, Kröger, N, Salwender, H, Metzner, B, Sezer, O, Engelhardt, M, Wolf, H-H, Einsele, H, Volpert, S, Heinecke, A, Berdel, WE & Kienast, J 2007, 'Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.', BRIT J HAEMATOL, vol. 138, no. 3, 3, pp. 330-337. <http://www.ncbi.nlm.nih.gov/pubmed/17614819?dopt=Citation>

APA

Kropff, M., Bisping, G., Schuck, E., Liebisch, P., Lang, N., Hentrich, M., Dechow, T., Kröger, N., Salwender, H., Metzner, B., Sezer, O., Engelhardt, M., Wolf, H-H., Einsele, H., Volpert, S., Heinecke, A., Berdel, W. E., & Kienast, J. (2007). Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. BRIT J HAEMATOL, 138(3), 330-337. [3]. http://www.ncbi.nlm.nih.gov/pubmed/17614819?dopt=Citation

Vancouver

Kropff M, Bisping G, Schuck E, Liebisch P, Lang N, Hentrich M et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. BRIT J HAEMATOL. 2007;138(3):330-337. 3.

Bibtex

@article{b74f7f8c496542409ee4eba0df43cdb7,
title = "Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.",
abstract = "A phase 2 trial was performed to study the combination of bortezomib (VELCADE) with intermediate-dose dexamethasone (DEX), and continuous low-dose oral cyclophosphamide (CY) in patients with relapsed multiple myeloma (MM). Fifty-four patients with advanced MM were enroled to receive eight 3-week treatment cycles with bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11, followed by three 5-week cycles with bortezomib 1.3 mg/m(2) on days 1, 8, 15, and 22. Within all cycles, DEX 20 mg/d was given orally on the day of bortezomib injection and the day thereafter. In addition, patients received CY continuous oral treatment at a dose of 50 mg/d p.o. once daily. Fifty patients completing at least one treatment cycle were evaluable for response. Complete, partial, and minor responses occurred in 16%, 66% and 8% of patients, respectively; overall response rate 90% (efficacy analysis). Median event-free survival was 12 months, with a median overall survival of 22 months. Adverse events (AE) of grades 3 or 4 occurring in at least 10% of patients comprised leucopenia, infection, herpes zoster, thrombocytopenia, neuropathy and fatigue. Bortezomib combined with DEX and CY is a highly effective treatment for relapsed MM at an acceptable rate of grade 3/4 AE. Antiviral prophylaxis appears to be mandatory.",
author = "Martin Kropff and Guido Bisping and Elke Schuck and Peter Liebisch and Nicola Lang and Markus Hentrich and Tobias Dechow and Nicolaus Kr{\"o}ger and Hans Salwender and Bernd Metzner and Orhan Sezer and Monika Engelhardt and Hans-Heinrich Wolf and Hermann Einsele and Sarah Volpert and Achim Heinecke and Berdel, {Wolfgang E} and Joachim Kienast",
year = "2007",
language = "Deutsch",
volume = "138",
pages = "330--337",
journal = "BRIT J HAEMATOL",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "3",

}

RIS

TY - JOUR

T1 - Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.

AU - Kropff, Martin

AU - Bisping, Guido

AU - Schuck, Elke

AU - Liebisch, Peter

AU - Lang, Nicola

AU - Hentrich, Markus

AU - Dechow, Tobias

AU - Kröger, Nicolaus

AU - Salwender, Hans

AU - Metzner, Bernd

AU - Sezer, Orhan

AU - Engelhardt, Monika

AU - Wolf, Hans-Heinrich

AU - Einsele, Hermann

AU - Volpert, Sarah

AU - Heinecke, Achim

AU - Berdel, Wolfgang E

AU - Kienast, Joachim

PY - 2007

Y1 - 2007

N2 - A phase 2 trial was performed to study the combination of bortezomib (VELCADE) with intermediate-dose dexamethasone (DEX), and continuous low-dose oral cyclophosphamide (CY) in patients with relapsed multiple myeloma (MM). Fifty-four patients with advanced MM were enroled to receive eight 3-week treatment cycles with bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11, followed by three 5-week cycles with bortezomib 1.3 mg/m(2) on days 1, 8, 15, and 22. Within all cycles, DEX 20 mg/d was given orally on the day of bortezomib injection and the day thereafter. In addition, patients received CY continuous oral treatment at a dose of 50 mg/d p.o. once daily. Fifty patients completing at least one treatment cycle were evaluable for response. Complete, partial, and minor responses occurred in 16%, 66% and 8% of patients, respectively; overall response rate 90% (efficacy analysis). Median event-free survival was 12 months, with a median overall survival of 22 months. Adverse events (AE) of grades 3 or 4 occurring in at least 10% of patients comprised leucopenia, infection, herpes zoster, thrombocytopenia, neuropathy and fatigue. Bortezomib combined with DEX and CY is a highly effective treatment for relapsed MM at an acceptable rate of grade 3/4 AE. Antiviral prophylaxis appears to be mandatory.

AB - A phase 2 trial was performed to study the combination of bortezomib (VELCADE) with intermediate-dose dexamethasone (DEX), and continuous low-dose oral cyclophosphamide (CY) in patients with relapsed multiple myeloma (MM). Fifty-four patients with advanced MM were enroled to receive eight 3-week treatment cycles with bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11, followed by three 5-week cycles with bortezomib 1.3 mg/m(2) on days 1, 8, 15, and 22. Within all cycles, DEX 20 mg/d was given orally on the day of bortezomib injection and the day thereafter. In addition, patients received CY continuous oral treatment at a dose of 50 mg/d p.o. once daily. Fifty patients completing at least one treatment cycle were evaluable for response. Complete, partial, and minor responses occurred in 16%, 66% and 8% of patients, respectively; overall response rate 90% (efficacy analysis). Median event-free survival was 12 months, with a median overall survival of 22 months. Adverse events (AE) of grades 3 or 4 occurring in at least 10% of patients comprised leucopenia, infection, herpes zoster, thrombocytopenia, neuropathy and fatigue. Bortezomib combined with DEX and CY is a highly effective treatment for relapsed MM at an acceptable rate of grade 3/4 AE. Antiviral prophylaxis appears to be mandatory.

M3 - SCORING: Zeitschriftenaufsatz

VL - 138

SP - 330

EP - 337

JO - BRIT J HAEMATOL

JF - BRIT J HAEMATOL

SN - 0007-1048

IS - 3

M1 - 3

ER -